Story Stocks^®

OmniAb (OABI) is rallying after announcing a new global collaboration and license agreement with Eli Lilly (LLY) for an ion channel program, adding another major pharma partner to its drug discovery platform. The deal includes an upfront payment, up to $370 mln in research, development, and commercial milestones, and tiered royalties on global net sales. OABI also raised its 2026 year-end cash and cash equivalents outlook to $49-53 mln from $37-41 mln, reflecting recent technology licensing activity.

• Why the deal stands out: OmniAb is a drug discovery technology company that partners with biopharma companies rather than developing most drugs itself, giving it multiple ways to participate economically as partner programs advance. The Lilly agreement plays directly into that model, leveraging OABI's technology platform and specialized ion channel discovery and screening capabilities, with economics spanning an upfront payment, potential milestones and royalties.
• Lilly relationship: The agreement provides further validation of OABI's ion channel capabilities from one of the industry's largest drug developers. The economics also extend beyond the initial upfront payment, with OABI eligible for research, development and commercial milestones, as well as tiered royalties on global net sales if a resulting product reaches commercialization.
• Q2: Earlier this month, OABI reported Q2 revenue of $13.4 mln, more than tripling from $3.9 mln a year ago, driven primarily by milestone revenue. Service revenue also increased primarily from the commencement of new ion channel programs. OABI ended Q2 with 110 active partners and 425 active programs, including 34 OmniAb-derived programs in clinical development or commercialization.
• Stock setup: Shares were already trading sharply higher heading into today, climbing roughly 70% from around $2 in late July and surging following OABI's Q2 results. The run has been supported by stronger milestone revenue, rising guidance and an expanding partner/program base, with today's agreement reinforcing that improving business-development backdrop.

Briefing.com Analyst Insight

OmniAb's Lilly agreement reinforces the appeal of its partner-driven model, where OABI can participate in drug-program economics without bearing the full burden of clinical development. The deal also validates its ion channel capabilities, while the increased year-end cash outlook improves near-term funding visibility. The main uncertainty is how much of the headline $370 mln milestone opportunity is ultimately realized and over what timeframe, since those payments depend on future research, development and commercial milestones. The undisclosed target and modality also limit visibility into the program's development path and commercial potential. Following the stock's sharp run since late July, continued licensing activity and progress across partnered programs will be important to sustaining the recent momentum.